Gerinnungsinhibitoren bei Sepsis und disseminierter intravasaler Gerinnung

  • J. Kienast
  • H. Ostermann
  • R. Mesters
Conference paper

Zusammenfassung

Eine grundlegende und für den deutschen Sprachraum prägende Definition der Sepsis geht auf H.Schottmüller zurück [68, 69]. Danach liegt eine Sepsis vor, „wenn sich innerhalb des Körpers ein Herd gebildet hat, von dem konstant oder periodisch pathogene Bakterien in den Blutkreislauf gelangen, und zwar derart, daß durch diese Invasion subjektive und objektive Krankheitserscheinungen ausgelöst werden“. Hiervon abweichend wird die Sepsis in der jüngeren angloamerikanischen Literatur als systemische Entzündungsreaktion auf eine aktive Infektion definiert, klinisch evident durch Fieber, Tachykardie, Tachypnoe und/oder Leukozytose bzw. Leukozytopenie [2]. Bei einer schweren Sepsis („severe sepsis“) treten Zeichen der inadäquaten Organperfusion oder Organdysfunktion wie Hypoxämie, Laktatanstieg, Oligurie oder Bewußtseinsstörungen hinzu [2]. Schwerste Verläufe fuhren zu Schock und Multiorganversagen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Abbink JJ, Nuijens JH, Eerenberg AJM et al. (1991) Quantification of functional and inactivated a2-macroglobulin in sepsis. Thromb Haemost 65: 32–39PubMedGoogle Scholar
  2. 2.
    American College of Chest Physicians (1992) Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20: 864–874CrossRefGoogle Scholar
  3. 3.
    Aoki Y, Ohishi R, Takei R et al. (1993) Effects of recombinant human soluble thrombomodulin (rhs-TM) on disseminated intravascular coagulation model in rats with decreased AT III level. Thromb Haemost 69: 736 (abstract)Google Scholar
  4. 4.
    Asakura H, Jokaji H, Saito M et al. (1991) Plasma levels of soluble thrombomodulin increase in cases of disseminated intravascular coagulation with organ failure. Am J Hematol 38: 281–287PubMedCrossRefGoogle Scholar
  5. 5.
    Bajaj MS, Rana SV, Wysolmerski RB, Bajaj SP (1987) Inhibitor of the factor Vila-tissue factor complex is reduced in patients with disseminated intravascular coagulation but not in patients with severe hepatocellular disease. J Clin Invest 79: 1874–1878PubMedCrossRefGoogle Scholar
  6. 6.
    Blauhut B, Necek S, Vinazzer H, Bergmann H (1982) Substitution therapy with an antithrombin III concentrate in shock and DIC. Thromb Res 27: 271–278PubMedCrossRefGoogle Scholar
  7. 7.
    Blauhut B, Kramar H, Vinazzer H, Bergmann H (1985) Substitution of antithrombin III in shock and DIC. A randomized study. Thromb Res 39: 81–89PubMedCrossRefGoogle Scholar
  8. 8.
    Boer JP de, Abbink J J, Brouwer MC et al. (1991) PAI-1 synthesis in the human hepatoma cell line Hep G2 is increased by cytokines — evidence that the liver contributes to acute phase behaviour of PAI-1. Thromb Haemost : 181–185PubMedGoogle Scholar
  9. 9.
    Brandtzaeg P, Sandset PM, Joo GB et al. (1989) The quantitative association of plasma endotoxin, antithrombin, protein C, extrinsic pathway inhibitor and fibrino-peptide A in systemic meningococcal disease. Thromb Res 55: 459–470PubMedCrossRefGoogle Scholar
  10. 10.
    Brandtzaeg P, Joo GB, Brusletto B, Kierulf P (1990) Plasminogen activator inhibitor 1 and 2, alpha-2-antiplasmin, plasminogen, and endotoxin levels in systemic meningococcal disease. Thromb Res 57: 271–278PubMedCrossRefGoogle Scholar
  11. 11.
    Comp PC, Esmon CT (1991) Regulatory mechanisms in hemostasis: Natural anticoagulants. In: Hoffman R, Benz EJ, Shattil SJ et al. (eds) Hematology. Basic principles and practice. Churchill Livingstone, New York, pp 1243–1251Google Scholar
  12. 12.
    Chuansumrit A, Manco-Johnson MJ, Hathaway WE (1989) Heparin cofactor II in adults and infants with thrombosis and DIC. Am J Hematol 31: 109–113PubMedCrossRefGoogle Scholar
  13. 13.
    Day KC, Hoffman LC, Palmier MO et al. (1990) Recombinant lipoprotein-associated coagulation inhibitor inhibits tissue thromboplastin-induced intravascular coagulation in the rabbit. Blood 76: 1538–1545PubMedGoogle Scholar
  14. 14.
    Deventer SJH van, Büller HR, ten Cate JW et al. (1990) Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 76: 2520–2526PubMedGoogle Scholar
  15. 15.
    Dofferhoff ASM, Bom VJJ, Vries-Hospers HG de et al. (1992) Patterns of cytokines, plasma endotoxin, plasminogen activator inhibior, and acute-phase proteins during the treatment of severe sepsis in humans. Crit Care Med 20: 185–192PubMedCrossRefGoogle Scholar
  16. 16.
    Emeis JJ, Kooistra T (1986) Interleukin 1 and lipopolysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. J Exp Med 163: 1260–1266PubMedCrossRefGoogle Scholar
  17. 17.
    Emerson TE, Fournel MA, Leach WJ, Redens TB (1987) Protection against disseminated intravascular coagulation and death by antithrombin III in the Escherichia coli endotoxemic rat. Circ Shock 21: 1–13PubMedGoogle Scholar
  18. 18.
    Emerson TE, Fournel MA, Redens TB et al. (1989) Efficacy of antithrombin III supplementation in animal models of fulminant Escherichia coli endotoxemia or bacteremia. Am J Med 87 (3B): 27–33CrossRefGoogle Scholar
  19. 19.
    Esmon CT, Taylor FB, Snow Tr (1991) Inflammation and coagulation: Lined processes potentially regulated through a common pathway mediated by protein C. Thromb Haemost 66: 160–165PubMedGoogle Scholar
  20. 20.
    Fourrier F, Chopin C, Goudemand J et al. (1992) Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 101: 816–823PubMedCrossRefGoogle Scholar
  21. 21.
    Fourrier F, Chopin C, Huart JJ et al. (1993) Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Workshop on Disseminated Intravascular Coagulation, Rauischholzhausen, May 12–14, 1993 (Abstract No. 14).Google Scholar
  22. 22.
    Frank D, Maurin N (1993) Sepsis and septic shock: haemostasis fibrinolysis equilibrium as a prognostic factor and an indicator during therapy. Thromb Haemost 69: 731 (abstract)Google Scholar
  23. 23.
    Hack CE, Voerman HJ, Eisele B et al. (1992) CI-esterase inhibitor substitution in sepsis. Lancet 1: 378CrossRefGoogle Scholar
  24. 24.
    Hack CE, Ogilvie AC, Eisele B et al. (1993) CI-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2. Intensive Care Med 19: 19–28CrossRefGoogle Scholar
  25. 25.
    Harper PL, Williamson L, Park G et al. (1991) A pilot study of antithrombin replacement in intensive care management: the effects on mortality, coagulation and renal function. Transfusion Med 1: 121–128CrossRefGoogle Scholar
  26. 26.
    Harper PL, Hermans JM, Carrell RW (1992) Recombinant natural anticoagulants: a review. J Royal Soc Med 85: 407–411Google Scholar
  27. 27.
    Heidinger K, Kemkes-Matthes B, Lasch HG (1993) Protein C and S in inflammatory diseases. Thromb Haemost 69: 725 (abstract)Google Scholar
  28. 28.
    Hellgren M, Javelin L, Hägnevik K, Blombäck M (1984) Antithrombin III concentrate as adjuvant in DIC treatment. A pilot study in 9 severely ill patients. Thromb Res 35: 459–466PubMedCrossRefGoogle Scholar
  29. 29.
    Hesselvik JF, Blombäck M, Brodin B, Maller R (1989) Coagulation, fibrinolysis and kallikrein systems in sepsis: Relation to outcome. Crit Care Med 17: 724–733PubMedCrossRefGoogle Scholar
  30. 30.
    Hesselvik JF, Mahn J, Dahlbäck B, Blombäck M (1991) Protein C, protein S and C4b-binding protein in severe infection and septic shock. Thromb Haemost : 126–129PubMedGoogle Scholar
  31. 31.
    Hinsbergh VWM van, Kooistra T, van de Berg EA et al. (1988) Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo. Blood 72: 1467–1473PubMedGoogle Scholar
  32. 32.
    Hoffman M, Pratt CW, Brown RL, Church FC (1989) Heparin cofactor II-proteinase reaction products exhibit neutrophil chemoattractant activity. Blood 73: 1682–1685PubMedGoogle Scholar
  33. 33.
    Inoue Y, Kohno S, Miyazaki T, Yamaguchi K (1991) Effect of a platelet activating factor antagonist and antithrombin III on septicemia and endotoxemia in rats. Tohoku J Exp Med 163: 175–185PubMedCrossRefGoogle Scholar
  34. 34.
    Jordan RE, Nelson RM, Kilpatrick J et al. (1989) Inactivation of human antithrombin by neutrophil elastase. J Biol Chem 264: 10493–10500PubMedGoogle Scholar
  35. 35.
    Juhan-Vague I, Aillaud MF, Cock F de et al. (1985) The fast-acting inhibitor of tissue plasminogen activator is an acute phase reactant protein. In: Davidson JF, Donati MB, Coccheri S (eds) Progress in fibrinolysis. Churchill Livingstone, Edinburgh p 146Google Scholar
  36. 36.
    Kaufman N, Page JD, Pixley RA et al. (1991) α2-Makroglobulin-kallikrein complexes detect contact system activation in hereditary angioedema and human sepsis. Blood 77: 2660–2667PubMedGoogle Scholar
  37. 37.
    Kruithof EKO, Nicoloso G, Bachmann F (1987) Plasminogen activator inhibitor 1: Development of a radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation. Blood 70: 1645–1653PubMedGoogle Scholar
  38. 38.
    Kruithof EKO, Calandra T, Pralong G et al. (1993) Evolution of plasminogen activator inhibitor type 1 in patients with septic shock — correlation with cytokine concentrations. Fibrinolysis 7: 117–121CrossRefGoogle Scholar
  39. 39.
    Laursen B, Mortensen JZ, Frost L, Hansen KB (1981) Disseminated intravascular coagulation in hepatic failure treated with antithrombin III. Thromb Res 22: 701–704PubMedCrossRefGoogle Scholar
  40. 40.
    Mammen EF, Miyakawa T, Phillips TF et al. (1985) Human antithrombin concentrates and experimental disseminated intravascular coagulation. Semin Thromb Hemost 11: 373–383PubMedCrossRefGoogle Scholar
  41. 41.
    Marlar RA, Endres-Brooks J, Miller C (1985) Serial studies of protein C and its plasma inhibitor in patients with disseminated intravascular coagulation. Blood 66: 59–63PubMedGoogle Scholar
  42. 42.
    McGuire EA, Tollefsen DM (1987) Activation of heparin cofactor II by fibroblasts and vascular smooth muscle cells. J. Biol Chem 262: 169–173PubMedGoogle Scholar
  43. 43.
    Mesters RM, Kienast J, Ostermann H, van de Loo J (1993) Tissue factor pathway inhibitor (TFPI) in septicemia: a prospective study in neutropenic patients. Thromb Haemost 69: 1198 (abstract)Google Scholar
  44. 44.
    Mourik JA van, Lawrence DA, Loskutoff DJ (1984) Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. J Biol Chem 159: 14914–14921Google Scholar
  45. 45.
    Novotny WF, Brown SG, Miletich JP et al. (1991) Plasma antigen levels of the lipo- protein-associated coagulation inhibitor in patient samples. Blood 78: 387–393PubMedGoogle Scholar
  46. 46.
    Nowak-Göttl U, Groll A, Kreuz WD et al. (1992) Behandlung der Verbrauchskoagu- lopathie mit Antithrombin III-Konzentrat bei Kindern mit nachgewiesener Sepsis. Klin Pädiatr 204: 134–140PubMedCrossRefGoogle Scholar
  47. 47.
    Nuijens JH, Eerenberg-Belmer AJM, Huijbregts CCM et al. (1989) Proteolytic inactivation of plasma Cl-inhibitor in sepsis. J Clin Invest 84: 443–450PubMedCrossRefGoogle Scholar
  48. 48.
    Nuijens JH, Abbink JJ, Wachtfogel YT et al. (1992) Plasma elastase at-antitrypsin and lactoferrin in sepsis: evidence for neutrophils as mediators in fatal sepsis. J Lab Clin Med 119: 159–168PubMedGoogle Scholar
  49. 49.
    Okajima K, Imamura H, Koga S et al. (1990) Treatment of patients with disseminated intravascular coagulation by protein C. Am J Hematol 33: 277–278PubMedCrossRefGoogle Scholar
  50. 50.
    Okamoto K, Takaki A, Takeda S et al. (1992) Coagulopathie in disseminated intravascular coagulation due to abdominal sepsis: determination of prothrombin fragment 1+2 and other markers. Haemostasis 22: 17–24PubMedGoogle Scholar
  51. 51.
    Owen MC, Brennan SO, Lewis JH, Carell RW (1983) Mutation of antitrypsin to antithrombin, alpha-1-antitrypsin Pittsburgh (358 Met-Arg), a fatal bleeding disorder. N Engl J Med 309: 694–698PubMedCrossRefGoogle Scholar
  52. 52.
    Páramo JA, Pérez JL, Serrano M, Rocha E (1990) Types 1 and 2 plasminogen activator inhibitor and tumor necrosis factor alpha in patients with sepsis.Thromb Haemost 64: 3–6Google Scholar
  53. 53.
    Parker KA, Tollefsen DM (1985) The protease specificity of heparin cofactor II. J Biol Chem 260: 3501–3505PubMedGoogle Scholar
  54. 54.
    Peters M, Fijnvandraat K, Derkx B et al. (1993) Severely reduced protein C levels predict a high mortality in meningococcal shock. Thromb Haemost 69: 1197 (abstract)Google Scholar
  55. 55.
    Philippé J, Offner F, Declerck PJ et al. (1991) Fibrinolysis and coagulation in patients with infectious disease and sepsis. Thromb Haemost : 291–295PubMedGoogle Scholar
  56. 56.
    Prager RL, Dunn EL, Kirsh MM, Penner JA (1979) Endotoxin-induced intravascular coagulation (DIC) and its therapy. Adv Shock Res 2: 277–287PubMedGoogle Scholar
  57. 57.
    Pralong G, Calandra T, Glauser MP et al. (1989) Plasminogen activator inhibitor 1: a prognostic marker in septic schock. Thromb Haemost 61: 459–462PubMedGoogle Scholar
  58. 57a.
    Rao LVM, Rapaport SI, Hoang AD (1993) Binding of factor VII a to tissue factor permits rapid antithrombin III/heparin inhibition of factor Villa. Blood 81: 2600–2607PubMedGoogle Scholar
  59. 58.
    Rapaport SI (1991) The extrinsic pathway inhibitor: A regulator of tissue factor- dependent blood coagulation. Thromb Haemost 66: 6–15PubMedGoogle Scholar
  60. 59.
    Redens TB, Leach WJ, Bogdanoff DA, Emerson TE (1988) Synergistic protection from lung damage by combining antithrombin-III and arproteinase inhibitor in the E. coli endotoxemic sheep pulmonary dysfunction model. Circ Shock 26: 15–26Google Scholar
  61. 60.
    Redens TB, Emerson TE (1989) Antithrombin III treatment limits disseminated intravascular coagulation in endotoxemia. Circ Shock 28: 49–58PubMedGoogle Scholar
  62. 61.
    Rivard GE, David M, Farrell C et al. (1993) Treatment of purpura fulminans in meningococcemia with protein C concentrate. Thromb Heamost 69: 1198 (abstract)Google Scholar
  63. 62.
    Sakata Y, Curriden S, Lawrence D et al. (1985) Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases antiactivator activity. Proc Natl Acad Sci USA 82: 1121–1125PubMedCrossRefGoogle Scholar
  64. 63.
    Sandset PM, Roise O, Aasen AO, Abildgard U (1989) Extrinsic pathway inhibitor in postoperative/posttraumatic septicemia: increased levels in fatal cases. Haemostasis 19: 189–195PubMedGoogle Scholar
  65. 64.
    Sandset PM, Warn-Cramer BJ, Maki SL, Rapaport SI (1991) Immunodepletion of extrinsic pathway inhibitor sensitizes rabbits to endotoxin-induced intravascular coagulation and the generalized Shwartzman reaction. Blood 78: 1496–1502PubMedGoogle Scholar
  66. 65.
    Sandset PM, Abildgaard U (1991) Extrinsic pathway inhibitor — the key to feedback control of blood coagulation initiated by tissue thromboplastin. Haemostasis 21: 219–239PubMedGoogle Scholar
  67. 66.
    Sandset PM; Warn-Cramer BJ, Rao LVM et al. (1991) Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiologic role for EPI as a natural anticoagulant. Proc Natl Acad Sci USA 88: 708–712PubMedCrossRefGoogle Scholar
  68. 67.
    Schipper HG, Jenkins CSP, Kahlé LH, ten Cate JW (1978) Antithrombin-III trans-fusion in disseminated intravascular coagulation. Lancet 1: 854–856PubMedCrossRefGoogle Scholar
  69. 68.
    Schottmüller H (1914) Wesen und Behandlung der Sepsis. Verh Dtsch Ges Inn Med 31: 257Google Scholar
  70. 69.
    Schuster HP (1989) Sepsis als Ursache des Multiorganversagens. Definition, Pathophysiologic und diagnostische Parameter. Anästh Intensivther Notfallmed 24: 206–211PubMedCrossRefGoogle Scholar
  71. 70.
    Seitz R, Wolf M, Egbring R et al. (1987) Participation and interactions of neutrophil elastase in haemostatic disorders of patients with severe infections. Eur J Haematol 38: 231–240PubMedCrossRefGoogle Scholar
  72. 71.
    Seitz R, Wolf M, Egbring R, Havemann K (1989) The disturbance of hemostasis in septic shock: role of neutrophil elastase and thrombin, effects of antithrombin III and plasma substitution. Eur J Haematol 43: 22–28PubMedCrossRefGoogle Scholar
  73. 72.
    Sprengers ED, Princen HMG, Kooistra T, Hinsbergh VWM van (1985) Inhibition of plasminogen activators by conditioned medium of human hepatocytes and hepatoma cell line Hep G2. J Lab Clin Med 105: 751–758PubMedGoogle Scholar
  74. 73.
    Suffredini AF, Harpel PC, Parillo JE (1989) Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 320: 1165–1172PubMedCrossRefGoogle Scholar
  75. 74.
    Taylor FB, Emerson TE, Jordan R et al. (1988) Antithrombin III prevents the lethal effects of Escherichia coli infusion in baboons. Circ Shock 26: 227–235PubMedGoogle Scholar
  76. 75.
    Tollefsen DM, Pestka CA, Monafo WJ (1983) Activation of heparin cofactor II by dermatan sulfate. J Biol Chem 258: 6713–6716PubMedGoogle Scholar
  77. 76.
    Tollefsen DM, Pestka CA (1985) Heparin cofactor II activity in patients with disseminated intravascular coagulation and hepatic failure. Blood 66: 769–774PubMedGoogle Scholar
  78. 77.
    Tran TH, Duckert F (1984) Heparin cofactor II determination — levels in normals and patients with hereditary antithrombin III deficiency and disseminated intravascular coagulation. Thromb Haemost 52: 112–116PubMedGoogle Scholar
  79. 78.
    Triantaphyllopoulos DC (1984) Effects of human antithrombin III on mortality and blood coagulation induced in rabbits by endotoxin. Thromb Haemost 51: 232–235PubMedGoogle Scholar
  80. 79.
    Vinazzer H (1989) Therapeutic use of antithrombin III in shock and disseminated intravascular coagulation. Semin Thromb Haemost 15: 347–352CrossRefGoogle Scholar
  81. 80.
    Voss R, Matthias FR, Borkowski G, Reitz D (1990) Activation and inhibition of fibrinolysis in septic patients in an internal intensive care unit. Br J Haematol 75: 99–105PubMedCrossRefGoogle Scholar
  82. 81.
    Wada H, Ohiwa M, Kaneko T et al. (1992) Plasma thrombomodulin as a marker of vascular disorders in thrombotic thrombocytopenic purpura and disseminated intravascular coagulation. Am J Hematol 39: 20–24PubMedCrossRefGoogle Scholar
  83. 82.
    Warr TA, Rao LVM, Rapaport SI (1989) Human plasma extrinsic pathway inhibitor activity: II. Plasma levels in disseminated intravascular coagulation and hepatocellular disease. Blood 74: 994–998PubMedGoogle Scholar
  84. 83.
    Wieding JU, Eisinger G, Köstering H (1989) Diagnostik der disseminierten intravasalen Gerinnung: Aussagekraft von löslichem Fibrin, D-Dimeren und Fibrin(ogen)- Spaltprodukten. Klin Wochenschr 67: 764–773PubMedCrossRefGoogle Scholar
  85. 84.
    Witt W, Fredrich M, Wydro R, Morser J (1993) Antithrombotic effects of recombinant soluble human thrombomodulin analogues in animal models of tissue-factor and thrombin induced DIC, Workshop on Disseminated Intravascular Coagulation, Rauischholzhausen, May 12–14 (Abstract No. 39)Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • J. Kienast
  • H. Ostermann
  • R. Mesters

There are no affiliations available

Personalised recommendations